NASDAQ · Biotechnology · USD
Lunai Bioworks Inc. (LNAI) Stock Analysis
Lunai Bioworks Inc. (LNAI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
LNAI Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.50
- Previous Close
- $0.52
- Day's Range
- 0.50–0.54
- 52-Week Range
- 0.46–13.28
- Volume
- 90.31K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.35
Valuation
- Market Cap
- $2.35M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 45.17
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −1.06
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$178.01M
- Shares Outstanding
- 4.53M
- 1-Year Return
- −94.90%
Dividend and dates
- Earnings Date
- November 12, 2026estimated
- Avg Volume
- 201.16K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, LNAI closed at $0.52, −94.90% over 1 year.
Lunai Bioworks Inc. (LNAI) has a market capitalization of $2.35M.
In fiscal 2025, LNAI reported revenue of $0.00.
LNAI Stock Return by Calendar Year
Lunai Bioworks Inc. (LNAI) return since Feb 2018: what $10,000 became
- 1 year
- $10,000 $510
- −94.90%
- 5 years
- $10,000 $8
- −99.92%
- Since Feb 2018
- $10,000 $11
- −99.89%
If you had invested $10,000 in Lunai Bioworks Inc. (LNAI) at the close on February 7, 2018, the earliest close on record here, it would have been worth $11 at the close on October 21, 2026: −99.89% in total, −54.31% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −92.66% |
| 2025 | −89.45% |
| 2024 | −73.63% |
| 2023 | +207.77% |
| 2022 | −85.87% |
| 2021 | +147.12% |
| 2020 | −41.24% |
| 2019 | −28.29% |
| 2018 (partial year) | +18.64% |
As of October 21, 2026.
LNAI Revenue and Earnings by Fiscal Year
FY ends June| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$178.01M | — |
| 2024 | $0.00 | −$88.43M | — |
| 2023 | $0.00 | −$39.68M | — |
| 2022 | $0.00 | −$113.43M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$18.55M | −$178.01M | — |
| 2024 | $0.00 | $0.00 | −$27.39M | −$88.43M | — |
| 2023 | $0.00 | $0.00 | −$19.60M | −$39.68M | — |
| 2022 | $0.00 | — | −$22.83M | −$113.43M | — |
Annual figures as reported, in the company's reporting currency. As of June 30, 2025.
LNAI Valuation vs Biotechnology Median
Median of 608 stocks| Metric | LNAI | Biotechnology median | vs median |
|---|---|---|---|
| P/S ratio | 45.17 | 13.30 | 3.4x the median |
Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
Lunai Bioworks Requests Immediate Nasdaq Trading Suspension Amid Allegations Of Short Selling And Failures To Deliver
BenzingaLunai Bioworks Files For Non Timely 10-K With U.S. SEC; Anticipates Reporting A Net Loss For The Fiscal Year Ended June 30, 2026 Of ~$3.2M
BenzingaLunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist Agreement
YahooLunai Bioworks Enters Exclusive Worldwide License And Collaboration Agreement With Tanaist To Add Human Cellular Phenotyping To Its Parkinson's Disease Discovery And Validation Platform
BenzingaLunai Bioworks (Nasdaq: LNAI) Demonstrates AI Chemical-Risk Screening for Generative AI
YahooLunai Bioworks Files Second Amended Complaint Against Six Registered Broker-Dealers And Two Broker-Dealer Principals As Defendants In U.S. District Court, Delaware
Benzinga
All 8 articles ↓Show fewer ↑
Lunai Bioworks Signs Master Collaboration Agreement With BrainStorm Therapeutics; BioSymetrics Publishes Parkinson's Disease AI White Paper, Initial Data Expected In 1H 2027
BenzingaLunai Bioworks Files Amended RICO Complaint Expanding Naked Short-Selling Lawsuit; Names 10 Defendants, Including 3 FINRA Registered Broker Dealers, In Connection With An Alleged Coordinated Naked Short Selling Scheme That The Company Says Generated Failures To Deliver On More Than 81% Of Its Outstanding Shares
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B